;PMID: 2506333
;source_file_947.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..108] = [t:52..108]
;2)sentence:[e:109..193] = [t:109..193]
;3)section:[e:197..263] = [t:197..263]
;4)section:[e:267..364] = [t:267..364]
;5)sentence:[e:368..576] = [t:368..576]
;6)sentence:[e:577..686] = [t:577..686]
;7)sentence:[e:687..868] = [t:687..868]
;8)sentence:[e:869..1067] = [t:869..1067]
;9)sentence:[e:1069..1182] = [t:1069..1182]
;10)sentence:[e:1183..1380] = [t:1183..1380]
;11)sentence:[e:1381..1703] = [t:1381..1703]
;12)sentence:[e:1704..1882] = [t:1704..1882]
;13)sentence:[e:1883..2152] = [t:1883..2152]
;14)section:[e:2156..2200] = [t:2156..2200]

;section 0 Span:0..46
;J Pharmacol Exp Ther. 1989 Sep;250(3):1034-42.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[22..26] 1989)
        (CC:[27..35] Sep;250-LRB-) (CD:[35..36] 3) (-RRB-:[36..37] -RRB-)
        (CD:[37..42] :1034) (TO:[42..43] -) (CD:[43..45] 42) (.:[45..46] .)))

;sentence 1 Span:52..108
;Suicide inactivation of cytochrome P-450 by methoxsalen.
;[76..92]:cyp450:"cytochrome P-450"
;[96..107]:substance:"methoxsalen"
(SENT
  (NP-HLN
    (NP (NN:[52..59] Suicide) (NN:[60..72] inactivation))
    (PP (IN:[73..75] of)
      (NP (NN:[76..86] cytochrome) (NN:[87..92] P-450)))
    (PP (IN:[93..95] by)
      (NP (NN:[96..107] methoxsalen)))
    (.:[107..108] .)))

;sentence 2 Span:109..193
;Evidence for the  covalent binding of a reactive intermediate to the protein
;moiety.
;[158..170]:substance:"intermediate"
;[178..185]:substance:"protein"
(SENT
  (NP-HLN
    (NP (NN:[109..117] Evidence))
    (PP (IN:[118..121] for)
      (NP
        (NP (DT:[122..125] the) (JJ:[127..135] covalent) (NN:[136..143] binding))
        (PP (IN:[144..146] of)
          (NP
            (NP (DT:[147..148] a) (JJ:[149..157] reactive)
                (NN:[158..170] intermediate))
            (PP (TO:[171..173] to)
              (NP (DT:[174..177] the) (NN:[178..185] protein)
                  (NN:[186..192] moiety)))))))
    (.:[192..193] .)))

;section 3 Span:197..263
;Labbe G, Descatoire V, Beaune P, Letteron P, Larrey D, Pessayre D.
(SEC
  (FRAG (NNP:[197..202] Labbe) (NNP:[203..204] G) (,:[204..205] ,)
        (NNP:[206..216] Descatoire) (NNP:[217..218] V) (,:[218..219] ,)
        (NNP:[220..226] Beaune) (NNP:[227..228] P) (,:[228..229] ,)
        (NNP:[230..238] Letteron) (NNP:[239..240] P) (,:[240..241] ,)
        (NNP:[242..248] Larrey) (NNP:[249..250] D) (,:[250..251] ,)
        (NNP:[252..260] Pessayre) (NNP:[261..263] D.)))

;section 4 Span:267..364
;Unite de Recherches de Physiopathologie Hepatique (INSERM U24), Hopital
;Beaujon,  Clichy, France.
(SEC
  (FRAG (NNP:[267..272] Unite) (NNP:[273..275] de) (NNP:[276..286] Recherches)
        (IN:[287..289] de) (NNP:[290..306] Physiopathologie)
        (NNP:[307..316] Hepatique) (-LRB-:[317..318] -LRB-)
        (NNP:[318..324] INSERM) (NNP:[325..328] U24) (-RRB-:[328..329] -RRB-)
        (,:[329..330] ,) (NNP:[331..338] Hopital) (NNP:[339..346] Beaujon)
        (,:[346..347] ,) (NNP:[349..355] Clichy) (,:[355..356] ,)
        (NNP:[357..363] France) (.:[363..364] .)))

;sentence 5 Span:368..576
;Incubation of rat liver microsomes with [3H]methoxsalen and NADPH resulted in
; the covalent binding of a methoxsalen intermediate to proteins comigrating
;with  cytochromes P-450 UT-A, PB-B/D, ISF-G and PCN-E.
;[408..423]:substance:"[3H]methoxsalen"
;[428..433]:substance:"NADPH"
;[473..484]:substance:"methoxsalen"
;[485..497]:substance:"intermediate"
;[501..509]:substance:"proteins"
;[528..550]:cyp450:"cytochromes P-450 UT-A"
;[528..545]...[570..575]:cyp450:"cytochromes P-450"..."PCN-E"
;[528..545]...[560..565]:cyp450:"cytochromes P-450"..."ISF-G"
;[528..545]...[552..554]...[557..558]:cyp450:"cytochromes P-450"..."PB"..."D"
;[528..545]...[552..556]:cyp450:"cytochromes P-450"..."PB-B"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[368..378] Incubation))
      (PP (IN:[379..381] of)
        (NP (NN:[382..385] rat) (NN:[386..391] liver)
            (NNS:[392..402] microsomes)))
      (PP (IN:[403..407] with)
        (NP (NN:[408..423] -LSB-3H-RSB-methoxsalen) (CC:[424..427] and)
            (NN:[428..433] NADPH))))
    (VP (VBD:[434..442] resulted)
      (PP-CLR (IN:[443..445] in)
        (NP
          (NP (DT:[447..450] the) (JJ:[451..459] covalent)
              (NN:[460..467] binding))
          (PP (IN:[468..470] of)
            (NP
              (NP (DT:[471..472] a) (NN:[473..484] methoxsalen))
              (ADJP (NN:[485..497] intermediate)
                (PP (TO:[498..500] to)
                  (NP
                    (NP (NNS:[501..509] proteins))
                    (VP (VBG:[510..521] comigrating)
                      (PP-CLR (IN:[522..526] with)
                        (NP
                          (NP
                            (NML-2 (NNS:[528..539] cytochromes)
                                   (NN:[540..545] P-450))
                            (NML (NN:[546..550] UT-A)))
                          (,:[550..551] ,)
                          (NP
                            (NP
                              (NML-2 (-NONE-:[551..551] *P*))
                              (NML-1 (NN:[552..554] PB) (HYPH:[554..555] -))
                              (NN:[555..556] B))
                            (SYM:[556..557] /)
                            (NP
                              (NML-2 (-NONE-:[557..557] *P*))
                              (NML-1 (-NONE-:[557..557] *P*))
                              (NN:[557..558] D)))
                          (,:[558..559] ,)
                          (NP
                            (NML-2 (-NONE-:[559..559] *P*))
                            (NN:[560..565] ISF-G))
                          (CC:[566..569] and)
                          (NP
                            (NML-2 (-NONE-:[569..569] *P*))
                            (NN:[570..575] PCN-E)))))))))))))
    (.:[575..576] .)))

;sentence 6 Span:577..686
;Binding was increased by  pretreatments with phenobarbital,
;beta-naphthoflavone (beta NF) and  dexamethasone.
;[622..635]:substance:"phenobarbital"
;[637..656]:substance:"beta-naphthoflavone"
;[658..665]:substance:"beta NF"
;[672..685]:substance:"dexamethasone"
(SENT
  (S
    (NP-SBJ-1 (NN:[577..584] Binding))
    (VP (VBD:[585..588] was)
      (VP (VBN:[589..598] increased)
        (NP-1 (-NONE-:[598..598] *))
        (PP (IN:[599..601] by)
          (NP-LGS
            (NP (NNS:[603..616] pretreatments))
            (PP (IN:[617..621] with)
              (NP
                (NP (NN:[622..635] phenobarbital))
                (,:[635..636] ,)
                (NP
                  (NP (NN:[637..656] beta-naphthoflavone))
                  (NP (-LRB-:[657..658] -LRB-)
                     (SYM:[658..662] beta) (NN:[663..665] NF)
                    (-RRB-:[665..666] -RRB-)))
                (CC:[667..670] and)
                (NP (NN:[672..685] dexamethasone))))))))
    (.:[685..686] .)))

;sentence 7 Span:687..868
;Such pretreatments also increased the loss of CO-binding capacity  either
;after administration of methoxsalen, or after incubation of hepatic 
;microsomes with methoxsalen and NADPH.
;[733..735]:substance:"CO"
;[785..796]:substance:"methoxsalen"
;[846..857]:substance:"methoxsalen"
;[862..867]:substance:"NADPH"
(SENT
  (S
    (NP-SBJ (JJ:[687..691] Such) (NNS:[692..705] pretreatments))
    (VP
      (ADVP (RB:[706..710] also))
      (VBD:[711..720] increased)
      (NP
        (NP (DT:[721..724] the) (NN:[725..729] loss))
        (PP (IN:[730..732] of)
          (NP
            (NML (NN:[733..735] CO) (HYPH:[735..736] -) (NN:[736..743] binding))
            (NN:[744..752] capacity))))
      (PP-TMP (CC:[754..760] either)
        (PP (IN:[761..766] after)
          (NP
            (NP (NN:[767..781] administration))
            (PP (IN:[782..784] of)
              (NP (NN:[785..796] methoxsalen)))))
        (,:[796..797] ,) (CC:[798..800] or)
        (PP (IN:[801..806] after)
          (NP
            (NP (NN:[807..817] incubation))
            (PP (IN:[818..820] of)
              (NP
                (NP (JJ:[821..828] hepatic) (NNS:[830..840] microsomes))
                (PP (IN:[841..845] with)
                  (NP (NN:[846..857] methoxsalen) (CC:[858..861] and)
                      (NN:[862..867] NADPH)))))))))
    (.:[867..868] .)))

;sentence 8 Span:869..1067
;Immunoprecipitation of the methoxsalen  metabolite-protein adducts in
;phenobarbital-induced microsomes was moderate with  anti-UT-A antibodies, but
;marked with anti-PB-B/D and anti-PCN-E antibodies.
;[896..919]:substance:"methoxsalen  metabolite"
;[920..935]:substance:"protein adducts"
;[939..952]:substance:"phenobarbital"
;[991..1011]:substance:"anti-UT-A antibodies"
;[1029..1038]...[1056..1066]:substance:"anti-PB-B"..."antibodies"
;[1029..1036]...[1039..1040]...[1056..1066]:substance:"anti-PB"..."D"..."antib
;odies"
;[1045..1066]:substance:"anti-PCN-E antibodies"
(SENT
  (S
    (NP-SBJ-3
      (NP (NN:[869..888] Immunoprecipitation))
      (PP (IN:[889..891] of)
        (NP (DT:[892..895] the)
          (NML
            (NML (NN:[896..907] methoxsalen) (NN:[909..919] metabolite))
            (HYPH:[919..920] -) (NN:[920..927] protein))
          (NNS:[928..935] adducts)))
      (PP-LOC (IN:[936..938] in)
        (NP
          (ADJP (NN:[939..952] phenobarbital) (HYPH:[952..953] -)
                (VBN:[953..960] induced))
          (NNS:[961..971] microsomes))))
    (VP (VBD:[972..975] was)
      (UCP
        (ADJP-PRD (JJ:[976..984] moderate)
          (PP (IN:[985..989] with)
            (NP
              (NML (AFX:[991..995] anti) (HYPH:[995..996] -)
                   (NN:[996..1000] UT-A))
              (NNS:[1001..1011] antibodies))))
        (,:[1011..1012] ,) (CC:[1013..1016] but)
        (VP (VBN:[1017..1023] marked)
          (NP-3 (-NONE-:[1023..1023] *))
          (PP (IN:[1024..1028] with)
            (NP
              (NP
                (NP
                  (NML-1 (AFX:[1029..1033] anti) (HYPH:[1033..1034] -)
                         (NN:[1034..1036] PB) (HYPH:[1036..1037] -))
                  (NN:[1037..1038] B)
                  (NML-2 (-NONE-:[1038..1038] *P*)))
                (SYM:[1038..1039] /)
                (NP
                  (NML-1 (-NONE-:[1039..1039] *P*))
                  (NN:[1039..1040] D)
                  (NML-2 (-NONE-:[1040..1040] *P*))))
              (CC:[1041..1044] and)
              (NP
                (NML (AFX:[1045..1049] anti) (HYPH:[1049..1050] -)
                     (NN:[1050..1055] PCN-E))
                (NML-2 (NNS:[1056..1066] antibodies))))))))
    (.:[1066..1067] .)))

;sentence 9 Span:1069..1182
;Immunoprecipitation was observed also with anti-ISF-G (anti-beta NF-B) 
;antibodies in beta NF-induced microsomes.
;[1112..1151]:substance:"anti-ISF-G (anti-beta NF-B)  antibodies"
;[1155..1162]:substance:"beta NF"
(SENT
  (S
    (NP-SBJ-1 (NN:[1069..1088] Immunoprecipitation))
    (VP (VBD:[1089..1092] was)
      (VP (VBN:[1093..1101] observed)
        (NP-1 (-NONE-:[1101..1101] *))
        (ADVP (RB:[1102..1106] also))
        (PP (IN:[1107..1111] with)
          (NP
            (NP
              (NML (AFX:[1112..1116] anti) (HYPH:[1116..1117] -)
                   (NN:[1117..1122] ISF-G)
                (PRN (-LRB-:[1123..1124] -LRB-)
                  (NML (AFX:[1124..1128] anti) (HYPH:[1128..1129] -)
                       (SYM:[1129..1133] beta) (NN:[1134..1138] NF-B))
                  (-RRB-:[1138..1139] -RRB-)))
              (NNS:[1141..1151] antibodies))
            (PP-LOC (IN:[1152..1154] in)
              (NP
                (ADJP
                  (NML (SYM:[1155..1159] beta) (NN:[1160..1162] NF))
                  (HYPH:[1162..1163] -) (VBN:[1163..1170] induced))
                (NNS:[1171..1181] microsomes)))))))
    (.:[1181..1182] .)))

;sentence 10 Span:1183..1380
;Methoxsalen (0.25 mM) inhibited  markedly the benzphetamine demethylase
;activity of phenobarbital-induced  microsomes and the erythromycin
;demethylase activity of dexamethasone-induced  microsomes.
;[1183..1194]:substance:"Methoxsalen"
;[1196..1200]:quantitative-value:"0.25"
;[1201..1203]:quantitative-units:"mM"
;[1229..1254]:substance:"benzphetamine demethylase"
;[1267..1280]:substance:"phenobarbital"
;[1309..1333]:substance:"erythromycin demethylase"
;[1346..1359]:substance:"dexamethasone"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1183..1194] Methoxsalen))
      (PRN (-LRB-:[1195..1196] -LRB-)
        (NP (CD:[1196..1200] 0.25) (NN:[1201..1203] mM))
        (-RRB-:[1203..1204] -RRB-)))
    (VP (VBD:[1205..1214] inhibited)
      (ADVP (RB:[1216..1224] markedly))
      (NP
        (NP
          (NP (DT:[1225..1228] the)
             (NN:[1229..1242] benzphetamine) (NN:[1243..1254] demethylase)
            (NN:[1255..1263] activity))
          (PP (IN:[1264..1266] of)
            (NP
              (ADJP (NN:[1267..1280] phenobarbital) (HYPH:[1280..1281] -)
                    (VBN:[1281..1288] induced))
              (NNS:[1290..1300] microsomes))))
        (CC:[1301..1304] and)
        (NP
          (NP (DT:[1305..1308] the)
             (NN:[1309..1321] erythromycin) (NN:[1322..1333] demethylase)
            (NN:[1334..1342] activity))
          (PP (IN:[1343..1345] of)
            (NP
              (ADJP (NN:[1346..1359] dexamethasone) (HYPH:[1359..1360] -)
                    (VBN:[1360..1367] induced))
              (NNS:[1369..1379] microsomes))))))
    (.:[1379..1380] .)))

;sentence 11 Span:1381..1703
;Whereas methoxsalen itself did not produce any binding spectrum, in  contrast
;either in vivo administration of methoxsalen or incubation in vitro  with
;methoxsalen and NADPH resulted in a low-to-high spin conversion of 
;cytochrome P-450 as suggested by the appearance of a spectrum analogous to a 
;type I binding spectrum.
;[1389..1400]:substance:"methoxsalen"
;[1492..1503]:substance:"methoxsalen"
;[1533..1544]:substance:"methoxsalen"
;[1549..1554]:substance:"NADPH"
;[1601..1617]:cyp450:"cytochrome P-450"
(SENT
  (S
    (SBAR-ADV (IN:[1381..1388] Whereas)
      (S
        (NP-SBJ (NN:[1389..1400] methoxsalen) (PRP:[1401..1407] itself))
        (VP (VBD:[1408..1411] did) (RB:[1412..1415] not)
          (VP (VB:[1416..1423] produce)
            (NP (DT:[1424..1427] any) (NN:[1428..1435] binding)
                (NN:[1436..1444] spectrum))))))
    (,:[1444..1445] ,)
    (PP (IN:[1446..1448] in)
      (NP (NN:[1450..1458] contrast)))
    (NP-SBJ (CC:[1459..1465] either)
      (NP
        (NP
          (ADJP (FW:[1466..1468] in) (FW:[1469..1473] vivo))
          (NN:[1474..1488] administration))
        (PP (IN:[1489..1491] of)
          (NP (NN:[1492..1503] methoxsalen))))
      (CC:[1504..1506] or)
      (NP
        (NP (NN:[1507..1517] incubation))
        (ADJP (FW:[1518..1520] in) (FW:[1521..1526] vitro))
        (PP (IN:[1528..1532] with)
          (NP (NN:[1533..1544] methoxsalen) (CC:[1545..1548] and)
              (NN:[1549..1554] NADPH)))))
    (VP (VBD:[1555..1563] resulted)
      (PP-CLR (IN:[1564..1566] in)
        (NP
          (NP (DT:[1567..1568] a)
            (ADJP (JJ:[1569..1572] low) (HYPH:[1572..1573] -)
              (PP (TO:[1573..1575] to) (HYPH:[1575..1576] -)
                (ADJP (JJ:[1576..1580] high))))
            (NN:[1581..1585] spin) (NN:[1586..1596] conversion))
          (PP (IN:[1597..1599] of)
            (NP (NN:[1601..1611] cytochrome) (NN:[1612..1617] P-450)))))
      (SBAR (IN:[1618..1620] as)
        (S
          (NP-SBJ-1 (-NONE-:[1620..1620] *))
          (VP (VBN:[1621..1630] suggested)
            (NP-1 (-NONE-:[1630..1630] *))
            (PP (IN:[1631..1633] by)
              (NP-LGS
                (NP (DT:[1634..1637] the) (NN:[1638..1648] appearance))
                (PP (IN:[1649..1651] of)
                  (NP
                    (NP (DT:[1652..1653] a) (NN:[1654..1662] spectrum))
                    (ADJP (JJ:[1663..1672] analogous)
                      (PP (TO:[1673..1675] to)
                        (NP (DT:[1676..1677] a)
                          (NML (NN:[1679..1683] type) (CD:[1684..1685] I))
                          (NN:[1686..1693] binding) (NN:[1694..1702] spectrum))))))))))))
    (.:[1702..1703] .)))

;sentence 12 Span:1704..1882
;This low-to-high spin conversion was apparently due to  a methoxsalen
;intermediate (probably, covalently bound to the protein and  preventing
;partial sixth ligation of the iron).
;[1762..1773]:substance:"methoxsalen"
;[1774..1786]:substance:"intermediate"
;[1822..1829]:substance:"protein"
;[1876..1880]:substance:"iron"
(SENT
  (S
    (NP-SBJ (DT:[1704..1708] This)
      (ADJP (JJ:[1709..1712] low) (HYPH:[1712..1713] -)
        (PP (TO:[1713..1715] to) (HYPH:[1715..1716] -)
          (ADJP (JJ:[1716..1720] high))))
      (NN:[1721..1725] spin) (NN:[1726..1736] conversion))
    (VP (VBD:[1737..1740] was)
      (ADVP (RB:[1741..1751] apparently))
      (PP-PRD (JJ:[1752..1755] due)
        (PP (TO:[1756..1758] to)
          (NP
            (NP (DT:[1760..1761] a) (NN:[1762..1773] methoxsalen)
                (NN:[1774..1786] intermediate))
            (PRN (-LRB-:[1787..1788] -LRB-)
              (VP
                (ADVP (RB:[1788..1796] probably))
                (,:[1796..1797] ,)
                (VP
                  (ADVP (RB:[1798..1808] covalently))
                  (VBN:[1809..1814] bound)
                  (NP (-NONE-:[1814..1814] *))
                  (PP-CLR (TO:[1815..1817] to)
                    (NP (DT:[1818..1821] the) (NN:[1822..1829] protein))))
                (CC:[1830..1833] and)
                (VP (VBG:[1835..1845] preventing)
                  (NP
                    (NP (JJ:[1846..1853] partial) (JJ:[1854..1859] sixth)
                        (NN:[1860..1868] ligation))
                    (PP (IN:[1869..1871] of)
                      (NP (DT:[1872..1875] the) (NN:[1876..1880] iron))))))
              (-RRB-:[1880..1881] -RRB-))))))
    (.:[1881..1882] .)))

;sentence 13 Span:1883..2152
;We conclude that suicide  inactivation of cytochrome P-450 by methoxsalen is
;related to the covalent  binding of a methoxsalen intermediate to the protein
;moiety of several  cytochrome P-450 isoenzymes (including UT-A, PB-B/D, PCN-E
;as well as ISF-G  and/or beta NF-B).
;[1925..1941]:cyp450:"cytochrome P-450"
;[1945..1956]:substance:"methoxsalen"
;[1998..2009]:substance:"methoxsalen"
;[2010..2022]:substance:"intermediate"
;[2030..2037]:substance:"protein"
;[2057..2084]:cyp450:"cytochrome P-450 isoenzymes"
;[2096..2100]:cyp450:"UT-A"
;[2102..2106]:cyp450:"PB-B"
;[2102..2104]...[2107..2108]:cyp450:"PB"..."D"
;[2110..2115]:cyp450:"PCN-E"
;[2127..2132]:cyp450:"ISF-G"
;[2141..2150]:cyp450:"beta NF-B"
(SENT
  (S
    (NP-SBJ (PRP:[1883..1885] We))
    (VP (VBP:[1886..1894] conclude)
      (SBAR (IN:[1895..1899] that)
        (S
          (NP-SBJ-2
            (NP (NN:[1900..1907] suicide) (NN:[1909..1921] inactivation))
            (PP (IN:[1922..1924] of)
              (NP (NN:[1925..1935] cytochrome) (NN:[1936..1941] P-450)))
            (PP (IN:[1942..1944] by)
              (NP (NN:[1945..1956] methoxsalen))))
          (VP (VBZ:[1957..1959] is)
            (VP (VBN:[1960..1967] related)
              (NP-2 (-NONE-:[1967..1967] *))
              (PP-CLR (TO:[1968..1970] to)
                (NP
                  (NP (DT:[1971..1974] the) (JJ:[1975..1983] covalent)
                      (NN:[1985..1992] binding))
                  (PP (IN:[1993..1995] of)
                    (NP (DT:[1996..1997] a) (NN:[1998..2009] methoxsalen)
                        (NN:[2010..2022] intermediate)))
                  (PP (TO:[2023..2025] to)
                    (NP
                      (NP (DT:[2026..2029] the) (NN:[2030..2037] protein)
                          (NN:[2038..2044] moiety))
                      (PP (IN:[2045..2047] of)
                        (NP
                          (NP (JJ:[2048..2055] several)
                            
                            (NML (NN:[2057..2067] cytochrome)
                                 (NN:[2068..2073] P-450))
                            (NNS:[2074..2084] isoenzymes))
                          (PRN (-LRB-:[2085..2086] -LRB-)
                            (PP (VBG:[2086..2095] including)
                              (NP
                                (NP (NN:[2096..2100] UT-A))
                                (,:[2100..2101] ,)
                                (NP
                                  (NP
                                    (NML-1 (NN:[2102..2104] PB)
                                           (HYPH:[2104..2105] -))
                                    (NN:[2105..2106] B))
                                  (SYM:[2106..2107] /)
                                  (NP
                                    (NML-1 (-NONE-:[2107..2107] *P*))
                                    (NN:[2107..2108] D)))
                                (,:[2108..2109] ,)
                                (NP (NN:[2110..2115] PCN-E))
                                (CONJP (RB:[2116..2118] as)
                                       (RB:[2119..2123] well)
                                       (IN:[2124..2126] as))
                                (NP (NN:[2127..2132] ISF-G))
                                (CC:[2134..2140] and/or)
                                (NP (SYM:[2141..2145] beta)
                                    (NN:[2146..2150] NF-B))))
                            (-RRB-:[2150..2151] -RRB-)))))))))))))
    (.:[2151..2152] .)))

;section 14 Span:2156..2200
;PMID: 2506333 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2156..2160] PMID) (::[2160..2161] :) (CD:[2162..2169] 2506333)
        (IN:[2170..2171] -LSB-) (NNP:[2171..2177] PubMed) (HYPH:[2178..2179] -)
        (JJ:[2180..2187] indexed) (IN:[2188..2191] for)
        (NNP:[2192..2200] MEDLINE-RSB-)))
